Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engelman

Showing results (141-150 of 238) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumorsPasi A Jänne, David S Boss, D Ross Camidge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancerSuresh S Ramalingam, David R Spigel, David Chen, et al.
Scientific Reports|February 4, 2016
A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2Susanne B Breitkopf, Xuemei Yang, Michael J Begley, et al.
Methods (San Diego, Calif.)|April 28, 2015
Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancerTimothy D O'Brien, Peilin Jia, Junfeng Xia, et al.
Molecular Cancer Therapeutics|May 10, 2019
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK InhibitorsHengyu Lu, Chen Liu, Roberto Velazquez, et al.
Cancer Discovery|May 16, 2012
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancersHihu Wing Cheung, Jinyan Du, Jesse S Boehm, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancerRebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.
Nature Medicine|December 14, 2011
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancersMichela Garofalo, Giulia Romano, Gianpiero Di Leva, et al.
The Journal of Clinical Investigation|August 15, 2006
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJeffrey A Engelman, Toru Mukohara, Kreshnik Zejnullahu, et al.
Cancer|February 7, 2014
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinibKaren L Reckamp, Giuseppe Giaccone, D Ross Camidge, et al.
Pageof 24

Showing results (141-150 of 238) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumorsPasi A Jänne, David S Boss, D Ross Camidge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancerSuresh S Ramalingam, David R Spigel, David Chen, et al.
Scientific Reports|February 4, 2016
A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2Susanne B Breitkopf, Xuemei Yang, Michael J Begley, et al.
Methods (San Diego, Calif.)|April 28, 2015
Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancerTimothy D O'Brien, Peilin Jia, Junfeng Xia, et al.
Molecular Cancer Therapeutics|May 10, 2019
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK InhibitorsHengyu Lu, Chen Liu, Roberto Velazquez, et al.
Cancer Discovery|May 16, 2012
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancersHihu Wing Cheung, Jinyan Du, Jesse S Boehm, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancerRebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.
Nature Medicine|December 14, 2011
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancersMichela Garofalo, Giulia Romano, Gianpiero Di Leva, et al.
The Journal of Clinical Investigation|August 15, 2006
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJeffrey A Engelman, Toru Mukohara, Kreshnik Zejnullahu, et al.
Cancer|February 7, 2014
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinibKaren L Reckamp, Giuseppe Giaccone, D Ross Camidge, et al.
Pageof 24